Prostate News and Research

RSS

Lower total cholesterol may be caused by undiagnosed cancer: Study

A pair of studies in Cancer Epidemiology, Biomarkers & Prevention, lay to rest the decades-long concern that lower total cholesterol may lead to cancer, and in fact lower cholesterol may reduce the risk of high-grade prostate cancer.

4 Nov 2009

Men with lower cholesterol less likely to develop high-grade prostate cancer

Men with lower cholesterol are less likely than those with higher levels to develop high-grade prostate cancer - an aggressive form of the disease with a poorer prognosis, according to results of a Johns Hopkins collaborative study.

4 Nov 2009

Blood vessels good indicators of prostate cancer behavior

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

4 Nov 2009

Early tolerance of proton therapy excellent in prostate cancer patients

Proton beam therapy can be safely delivered to men with prostate cancer and has minimal urinary and rectal side effects, according to a study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

Calypso Medical Technologies presents its real-time tracking technology at 51st ASTRO annual meeting

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced Calypso’s real-time tracking technology is included in 36 scientific presentations and posters at the 51st Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), now underway at McCormick Place in Chicago.

3 Nov 2009

AAPM Task Group issues new radiation guidelines for brachytherapy

Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient, according to a new guideline co-authored by Yan Yu, Ph.D., director of Medical Physics in the department of Radiation Oncology at Thomas Jefferson University.

3 Nov 2009

Extra dose of proton radiation therapy reduces prostate cancer recurrences

Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

Dendreon Corporation today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S. Food and Drug Administration (FDA). Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

2 Nov 2009

FDA issues a Complete Response Letter for GTx' toremifene NDA

GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).

2 Nov 2009

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.

2 Nov 2009

New CyberKnife Robotic Radiosurgery System from Accuray

Accuray Incorporated, a global leader in the field of radiosurgery, announced today the introduction of the CyberKnife(®) VSI(TM) System, the latest addition to the CyberKnife product family.

1 Nov 2009

Congressman Mike Thompson lauded for endorsing the Lung Cancer Mortality Reduction Act

Today, Lung Cancer Alliance (LCA) praised Congressman Mike Thompson (D-CA) for his endorsement of the Lung Cancer Mortality Reduction Act of 2009. Thompson joins Representatives Michael Honda (D-CA), Barbara Lee (D-CA) and Lucille Roybal-Allard (D-CA) in strengthening California's Congressional support for this critically needed legislation.

31 Oct 2009

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that 28 CyberKnife-focused abstracts have been accepted as part of the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place November 1 - 5 in Chicago, Illinois. This represents a 27 percent increase in CyberKnife abstracts over last year's Annual Meeting.

31 Oct 2009

NIH awards Charles Drew University $9.8M to reduce cancer health disparities in underserved populations

Charles Drew University has been awarded $9.8 million from three major national funders to support the university's long-term, UCLA partnership aimed at reducing the risk of cancer among minorities in poor and disadvantaged communities.

30 Oct 2009

Merge Healthcare and MEDRAD announce an expansion of their EU Distribution Agreement for CADstream

Merge Healthcare, a health IT solutions leader, and MEDRAD, a leading provider of medical devices and services for diagnostic imaging, today announced an expansion of their European Union Distribution Agreement for CADstream, a dedicated CAD system for MRI.

30 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

ASTRO to host news briefings on top cancer research papers

The American Society for Radiation Oncology (ASTRO) will host four news briefings with accompanying live webcasts on the top cancer research papers from its 51st Annual Meeting.

30 Oct 2009

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.

30 Oct 2009

Heidelberg Ion Radiation Therapy Center established; European patients can benefit from new radiation therapy

A new, innovative form of radiation based on verified scientific facts will be available to patients all over Europe within the next few decades. The official kick-off meeting of the Community project ULICE (Union of LIght Ions Centres in Europe), which the European Union is supporting with nearly 10 million euros, was held in fall 2009 in the Department of Radiooncology and Radiation Therapy of the Heidelberg University Hospital.

30 Oct 2009

Research provides new insight on gene fusion, a phenomenon known to cause prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have discovered what leads to two genes fusing together, a phenomenon that has been shown to cause prostate cancer to develop.

30 Oct 2009

Prostate News and Research

Lower total cholesterol may be caused by undiagnosed cancer: Study

Men with lower cholesterol less likely to develop high-grade prostate cancer

Blood vessels good indicators of prostate cancer behavior

Early tolerance of proton therapy excellent in prostate cancer patients

Calypso Medical Technologies presents its real-time tracking technology at 51st ASTRO annual meeting

AAPM Task Group issues new radiation guidelines for brachytherapy

Extra dose of proton radiation therapy reduces prostate cancer recurrences

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

FDA issues a Complete Response Letter for GTx' toremifene NDA

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

New CyberKnife Robotic Radiosurgery System from Accuray

Congressman Mike Thompson lauded for endorsing the Lung Cancer Mortality Reduction Act

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

NIH awards Charles Drew University $9.8M to reduce cancer health disparities in underserved populations

Merge Healthcare and MEDRAD announce an expansion of their EU Distribution Agreement for CADstream

Eisai reports global Phase III study results of eribulin mesylate

ASTRO to host news briefings on top cancer research papers

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Heidelberg Ion Radiation Therapy Center established; European patients can benefit from new radiation therapy

Research provides new insight on gene fusion, a phenomenon known to cause prostate cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News